Filspari (Sparsentan) Patent Expiration, LOE Window & CMS Spending

Filspari (Sparsentan) by Travere Therapeutics: FDA Orange Book LOE 2037-10-13, 0 AB generics, $40.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTravere Therapeutics
FDA Application & PathwayN216403 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-10-13
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40.6M
2024 Medicare Part D Spend$24.3M
2024 Medicaid Spend$16.3M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 33.0% 2-yr change)